NASDAQ:VLRX - Valeritas Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.4069 0.00 (0.00 %) (As of 01/18/2019 04:00 PM ET)Previous Close$0.4069Today's Range$0.3950 - $0.4252-Week Range$0.30 - $4.58Volume743,626 shsAverage Volume1.44 million shsMarket Capitalization$10.17 millionP/E RatioN/ADividend YieldN/ABeta1.38 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery. In addition, its products include V-Go Prefill, which is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go Link that is in the early stages of development for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors in the United States. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey. Receive VLRX News and Ratings via Email Sign-up to receive the latest news and ratings for VLRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VLRX Previous Symbol CUSIPN/A Webwww.valeritas.com Phone908-927-9920Debt Debt-to-Equity Ratio13.66 Current Ratio3.00 Quick Ratio2.47Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$20.25 million Price / Sales0.50 Cash FlowN/A Price / Cash FlowN/A Book Value($0.59) per share Price / Book-0.69Profitability EPS (Most Recent Fiscal Year)($8.29) Net Income$-49,300,000.00 Net Margins-193.79% Return on EquityN/A Return on Assets-102.96%Miscellaneous Employees103 Outstanding Shares24,950,000Market Cap$10.17 million OptionableNot Optionable Valeritas (NASDAQ:VLRX) Frequently Asked Questions What is Valeritas' stock symbol? Valeritas trades on the NASDAQ under the ticker symbol "VLRX." How were Valeritas' earnings last quarter? Valeritas Holdings Inc (NASDAQ:VLRX) issued its quarterly earnings results on Friday, November, 9th. The company reported ($0.49) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.07. The company had revenue of $6.93 million for the quarter. View Valeritas' Earnings History. When is Valeritas' next earnings date? Valeritas is scheduled to release their next quarterly earnings announcement on Monday, February 25th 2019. View Earnings Estimates for Valeritas. What guidance has Valeritas issued on next quarter's earnings? Valeritas updated its FY 2018 earnings guidance on Friday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $26-26.5 million, compared to the consensus revenue estimate of $26.85 million. What price target have analysts set for VLRX? 4 Wall Street analysts have issued 12 month price targets for Valeritas' stock. Their predictions range from $1.00 to $3.50. On average, they expect Valeritas' share price to reach $2.1667 in the next year. This suggests a possible upside of 432.5% from the stock's current price. View Analyst Price Targets for Valeritas. What is the consensus analysts' recommendation for Valeritas? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Valeritas in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Valeritas. Has Valeritas been receiving favorable news coverage? Media headlines about VLRX stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Valeritas earned a daily sentiment score of 1.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. Are investors shorting Valeritas? Valeritas saw a increase in short interest during the month of December. As of December 14th, there was short interest totalling 2,674,132 shares, an increase of 51.9% from the November 30th total of 1,760,954 shares. Based on an average daily volume of 1,485,489 shares, the days-to-cover ratio is currently 1.8 days. Approximately 3.5% of the shares of the stock are sold short. View Valeritas' Current Options Chain. Who are some of Valeritas' key competitors? Some companies that are related to Valeritas include AIT Therapeutics (AITB), Obalon Therapeutics (OBLN), SANUWAVE Health (SNWV), Nephros (NEPH), Restoration Robotics (HAIR), Interpace Diagnostics Group (IDXG), PAVmed (PAVM), Lianluo Smart (LLIT), Dynatronics (DYNT), Neovasc (NVCN), DarioHealth (DRIO), Hancock Jaffe Laboratories (HJLI), CELLECT BIOTECH/S (APOP), Invivo Therapeutics (NVIV) and Biostage (BSTG). Who are Valeritas' key executives? Valeritas' management team includes the folowing people: Mr. John E. Timberlake, Pres, CEO & Director (Age 54)Mr. Erick J. Lucera CPA, CFA, Chief Financial Officer (Age 51)Mr. Geoffrey H. Jenkins, Exec. VP of Manufacturing, Operations and R&D (Age 67)Dr. Matthew H. Nguyen, Chief Commercial Officer (Age 49)Mr. Scott A. Huie, VP of Regulatory Affairs/Quality Assurance and Compliance When did Valeritas IPO? (VLRX) raised $60 million in an initial public offering (IPO) on Thursday, March 23rd 2017. The company issued 6,000,000 shares at a price of $9.00-$11.00 per share. Cowen and Company and Wedbush PacGrow served as the underwriters for the IPO and Roth Capital Partners and B. Riley & Co. were co-managers. How do I buy shares of Valeritas? Shares of VLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Valeritas' stock price today? One share of VLRX stock can currently be purchased for approximately $0.4069. How big of a company is Valeritas? Valeritas has a market capitalization of $10.17 million and generates $20.25 million in revenue each year. The company earns $-49,300,000.00 in net income (profit) each year or ($8.29) on an earnings per share basis. Valeritas employs 103 workers across the globe. What is Valeritas' official website? The official website for Valeritas is http://www.valeritas.com. How can I contact Valeritas? Valeritas' mailing address is 750 ROUTE 202 SOUTH SUITE 600, BRIDGEWATER NJ, 08807. The company can be reached via phone at 908-927-9920 or via email at [email protected] MarketBeat Community Rating for Valeritas (NASDAQ VLRX)Community Ranking: 3.2 out of 5 ( )Outperform Votes: 153 (Vote Outperform)Underperform Votes: 89 (Vote Underperform)Total Votes: 242MarketBeat's community ratings are surveys of what our community members think about Valeritas and other stocks. Vote "Outperform" if you believe VLRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VLRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/19/2019 by MarketBeat.com StaffFeatured Article: What is cost of equity?